Matuzumab Treatment With Epirubicin, Cisplatin and Capecitabine (ECX) in Esophago-Gastric Cancer
Clinical trial NCT00215644 · COMPLETED
Trial details
- NCT number
- NCT00215644
- Sponsor
- Merck KGaA, Darmstadt, Germany
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2005-08-31
- Primary completion
- 2008-07-31
- Enrollment
- 72
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.